Active, not recruitingPhase 3NCT04221477
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
Studying Pediatric systemic lupus erythematosus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 271 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2020 – 2031
Study locations (30)
- University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States
- Wallace Rheumatic Study Center, Beverly Hills, California, United States
- Kaiser Permanente - Fontana, Fontana, California, United States
- Kaiser Permanente - San Francisco Medical Center, San Francisco, California, United States
- Stanford University Medical Center, Stanford, California, United States
- Univ Colorado Health Sci Ctr, Aurora, Colorado, United States
- Yale Medical Group, New Haven, Connecticut, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Georgia Nephrology, Lawrenceville, Georgia, United States
- North Shore University Hospital, Manhasset, New York, United States
- NYU Langone Medical Center, New York, New York, United States
- Columbia University Medical Center, New York, New York, United States
- AD-CARE, University of Rochester Medical Center, Rochester, New York, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04221477 on ClinicalTrials.govOther trials for Pediatric systemic lupus erythematosus
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07425730Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric LupusShanghai Jiao Tong University School of Medicine
- RECRUITINGEARLY PHASE1NCT07339332A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus ErythematosusUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE1NCT07109986UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus NephritisNanjing IASO Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGNANCT07196072A Multi-component, Person-centered, and Yoga-based Coaching Program for Lupus Chronic PainUniversity of Michigan
- RECRUITINGNCT07128966Direct to Patient Minimal Risk Biospecimen and Data Collection ResearchJoined Bio
- RECRUITINGNCT06659029Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab UsersAstraZeneca
- RECRUITINGPHASE1NCT06613360A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus ErythematosusCullinan Therapeutics Inc.
- RECRUITINGNCT07017868Correlation Between Serum Uric Acid, Serum Homocysteine Level and Interleukin- 17 in Lupus Nephritis PatientsSohag University